Letter to the EditorFull Access
Published Online:1 Feb 2006https://doi.org/10.1176/appi.ajp.163.2.325
- Cited by
- Psychiatry Research, Vol. 303
- IJC Heart & Vasculature, Vol. 40
- SSRN Electronic Journal, Vol. 3
- 4 May 2018 | Therapeutic Advances in Drug Safety, Vol. 9, No. 6
- François R. Girardin,
M.D., M.Sc. , - Marianne Gex-Fabry,
Ph.D. , - Patricia Berney,
M.D. , - Dipen Shah,
M.D. , - Jean-Michel Gaspoz,
M.D., M.Sc. , and - Pierre Dayer,
M.D.
1 December 2013 | American Journal of Psychiatry, Vol. 170, No. 12- François R. Girardin,
- 4 September 2013 | Therapeutic Advances in Drug Safety, Vol. 4, No. 5
- 16 December 2012 | Investigational New Drugs, Vol. 31, No. 4
- 5 April 2012 | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 30, No. 3
- 1 February 2009 | Therapeutic Advances in Cardiovascular Disease, Vol. 3, No. 1
- 1 September 2008 | Pediatrics, Vol. 122, No. 3
- 29 January 2009 | British Journal of Pharmacology, Vol. 149, No. 5
- 29 January 2009 | British Journal of Pharmacology, Vol. 149, No. 5
- 1 January 2006 | International Journal of Geriatric Psychiatry, Vol. 21, No. 9
- 1 January 2006 | Pharmacoepidemiology and Drug Safety, Vol. 15, No. 8